BRAF and melanoma: Targeted therapies, such as vemurafenib and dabrafenib, have shown remarkable efficacy in patients with BRAF-mutant melanoma; however, resistance often develops due to the activation of alternative signaling pathways or the emergence of resistant subclones [21].